TSX:ONC - Toronto Stock Exchange - CA6823108759 - Common Stock - Currency: CAD
ONCOLYTICS BIOTECH INC
TSX:ONC (2/7/2025, 7:00:00 PM)
1.09
-0.05 (-4.39%)
The current stock price of ONC.CA is 1.09 CAD. In the past month the price decreased by -12.8%. In the past year, price decreased by -21.58%.
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:GSK),(NASDAQ:AZN),(NASDAQ:GILD),(NYSE:BMY) EQNX::TICKER_END
Pelareorep combination therapy shows continued meaningful improvement over checkpoint inhibitors alone in anal cancer patients Pelareorep-based therapy demonstrates strong safety profile with new chemotherapy regimen in pancreatic cancer patients SAN DIEGO, CA and CALGARY, AB – January 22, 2025 – Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in […]
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC) EQNX::TICKER_END
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:GSK),(NASDAQ:AZN),(NYSE:ABBV),(NASDAQ:CRDF) EQNX::TICKER_END
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
FRX.CA | FENNEC PHARMACEUTICALS INC | N/A | 247.78M | ||
BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 236.47M | ||
EDT.CA | SPECTRAL MEDICAL INC | N/A | 166.88M | ||
EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 163.85M | ||
TH.CA | THERATECHNOLOGIES INC | N/A | 105.75M | ||
MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 99.26M | ||
COV.CA | COVALON TECHNOLOGIES LTD | 28.09 | 84.67M | ||
MSCL.CA | SATELLOS BIOSCIENCE INC | N/A | 79.27M | ||
MBX.CA | MICROBIX BIOSYSTEMS INC | 16.5 | 66.59M | ||
SVA.CA | SERNOVA CORP | N/A | 55.07M | ||
HBP.CA | HELIX BIOPHARMA CORP | N/A | 44.12M | ||
MDCX.CA | MEDICUS PHARMA LTD | N/A | 41.77M |
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta. The company went IPO on 2000-06-01. The firm is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
ONCOLYTICS BIOTECH INC
804, 322 - 11 Avenue Sw, Calgary Alberta Canada T2n 1X7
Calgary ALBERTA T2N 1X7 CA
CEO: Matthew C. Coffey
Employees: 29
Company Website: https://www.oncolyticsbiotech.com/
Investor Relations: http://www.oncolyticsbiotech.com/investor-centre/investor-overview/
Phone: 14036707377
The current stock price of ONC.CA is 1.09 CAD.
The exchange symbol of ONCOLYTICS BIOTECH INC is ONC and it is listed on the Toronto Stock Exchange exchange.
ONC.CA stock is listed on the Toronto Stock Exchange exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ONC.CA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ONC.CA.
ONC.CA does not pay a dividend.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | N/A | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 80% to ONC.CA. The Buy consensus is the average rating of analysts ratings from 11 analysts.